Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
J Headache Pain
.
2021 Aug 26;22(1):100.
doi: 10.1186/s10194-021-01307-6.
Authors
Michael Ament
1
,
Kathleen Day
2
,
Virginia L Stauffer
3
,
Vladimir Skljarevski
3
,
Mallikarjuna Rettiganti
3
,
Eric Pearlman
3
,
Sheena K Aurora
3
Affiliations
1
Ament Headache Center, Denver, CO, 80206, USA.
2
Eli Lilly and Company, Indianapolis, IN, 46285, USA. day_kathleen_ann@lilly.com.
3
Eli Lilly and Company, Indianapolis, IN, 46285, USA.
PMID:
34445967
PMCID:
PMC8393809
DOI:
10.1186/s10194-021-01307-6
No abstract available
Publication types
Published Erratum